Syed Naseeruddin, MD
Adult Medicine · Saint Cloud, FLNPI 1235187527
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AstraZeneca at 29.0% of the total. Reporting peaked in 2023 at $1,470 and has fallen 83.8% since, to $238 in 2025. Among adult medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$505
- Novo Nordisk$467
- Boehringer Ingelheim$371
- Pfizer$326
- Novartis$326
- plus $2K from 20 others
Across 14 payments — averaging $1521.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cipla USA Inc.$14K
- AstraZeneca$7K
- Teva Pharmaceuticals USA, Inc.$29
What the payments were for
- Food & beverage$5,412100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $1,570 |
| GSK | 34 | $505 |
| Novo Nordisk | 27 | $467 |
| Boehringer Ingelheim | 16 | $371 |
| Pfizer | 15 | $326 |
| Novartis | 11 | $326 |
| Lilly USA, LLC | 18 | $303 |
| Merck | 13 | $258 |
| Bayer | 10 | $240 |
| Exact Sciences | 7 | $228 |
| Johnson & Johnson(2 entities) | 8 | $152 |
| Amgen | 5 | $97 |
| Amarin Pharma, Inc. | 5 | $92 |
| AbbVie | 4 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $78 |
| Sunovion Pharmaceuticals Inc. | 3 | $65 |
| Scilex Pharmaceuticals Inc. | 3 | $49 |
| Mylan Specialty L.p. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Lundbeck LLC | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,412 in reported general payments places this provider in the 90th percentile of 195 adult medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 183 | $210,703 |
| JardianceEmpagliflozin | 128 | $193,058 |
| FarxigaDapagliflozin Propanediol | 134 | $185,820 |
| EliquisApixaban | 112 | $146,528 |
| JanuviaSitagliptin Phosphate | 59 | $75,544 |
| TrulicityDulaglutide | 25 | $44,428 |
| EntrestoSacubitril/Valsartan | 28 | $39,043 |
| SymbicortBudesonide/Formoterol Fumarate | 84 | $26,481 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $24,568 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $22,216 |
| LinzessLinaclotide | 19 | $19,751 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $19,165 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $16,094 |
| MyrbetriqMirabegron | 22 | $15,197 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 91 | $14,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $1,570 | $231,465233 claims |
| Novo NordiskOzempic | $467 | $210,703183 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $371 | $209,357157 claims |
| PfizerEliquis | $326 | $146,528112 claims |
| MerckJanuvia | $258 | $75,54459 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $505 | $51,33170 claims |
| Lilly USA, LLCTrulicity | $303 | $44,42825 claims |
| NovartisEntresto | $326 | $39,04328 claims |
| AbbVieLinzess | $81 | $19,75119 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $78 | $8,85140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 195 adult medicine providers in Florida.
Other adult medicine in Saint Cloud
- Steven SantiagoMiami$290K
- Tammy DsouzaKissimmee$191K
- Eric SchertzerPlantation$26K
- Ricardo SerranoMerritt Island$20K
- Marlene JarinMiami Beach$18K
- Myra ReedPanama City Beach$16K
- Joshua RycusCoral Springs$13K
- Frederick WeigandDeltona$9K
- Hernando ChongMiami$9K
- Neri FranzonFt Lauderdale$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.